OVX-033 is under clinical development by Osivax and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering ...

12月23日，贵州大学绿色农药全国重点实验室博士生王艳菊在Aggregate (影响因子IF=13.9)期刊发表了题为“A Vanillin‐Derived Inhibitor of Aggregates via Targeting ...

INR:7791. india versus australia t20 world cup live AbbVie/Roche's Venclexta+Gazyva combination for CLL approved in Canada ...

INR:5127. world cup final 2024 venue Zhimeng Pharmaceuticals' anti-HBV nucleocapsid inhibitor ZM-H1505R was approved for clinical trials Endoscope lead ...

INR:0084. pakistan vs bangladesh t20 Zhimeng Pharmaceuticals' anti-HBV nucleocapsid inhibitor ZM-H1505R was approved for clinical trials Big news for c ...

This is the first time the blood services researchers have been able to look for two types of antibodies. One test indicates if a sample has antibodies to the nucleocapsid proteins (anti-nucleocapsid ...

OVX-836 is under clinical development by Osivax and currently in Phase II for Unspecified Influenza Virus Infections.

Crown Perth Sports Bar schedule Eli Lilly's Cyramza combined with erlotinib is approved by the FDA for first-line treatment of EGFR-muta ...

To fight the virus that causes influenza, one of the avenues being explored by scientists is the development of drugs capable of destabilizing its genome, made up of eight RNA molecules. But the ...

To fight the virus that causes influenza, one of the avenues being explored by scientists is the development of drugs capable of destabilizing its genome, made up of eight RNA molecules.